BELLEVUE, WA, June 9 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY)
(the "Company") today announced that Daniel K. Spiegelman and Stephen K.
Burley, M.D., D.Phil. have joined its board of directors for three-year terms.
The Company also announced the retirement of S. Robert Blair from the board of
Mr. Spiegelman is Senior Vice President and Chief Financial Officer at CV
Therapeutics in Palo Alto, California. He will assume the chairmanship of the
audit committee at Oncothyreon on July 1, 2008. Dr. Burley is Chief Scientific
Officer and Senior Vice President at SGX Pharmaceuticals, Inc., and Adjunct
Professor at both the Rockefeller University and the University of California
in San Diego.
"We are very pleased that Dan Spiegelman and Stephen Burley will be
bringing their financial and scientific expertise and leadership to our board
of directors," said Christopher S. Henney, Ph.D., Chairman of the board of
directors at Oncothyreon. "We are also grateful for the many years of service
which Bob Blair has given to this Company."
Oncothyreon is a biotechnology company specializing in the development of
innovative therapeutic products for the treatment of cancer. Oncothyreon's
goal is to develop and commercialize novel synthetic vaccines and targeted
small molecules that have the potential to improve the lives and outcomes of
cancer patients. For more information visit www.oncothyreon.com.
Additional information relating to Oncothyreon can be found on U.S. EDGAR
at www.sec.gov and on SEDAR at www.sedar.com.
For further information:
For further information: Investor and Media Relations Contact: Julie
Rathbun, Rathbun Communications, (206) 769-9219, email@example.com